EVerZom’s ambition is to transform regenerative medicine and the field of biotherapies thanks to these biological nanoparticles, the extracellular vesicles.
EVerZom, a biopharmaceutical company specializing in the bioproduction of extracellular vesicles, announced today that it has obtained €1.1 million in funding from institutional and private investors to develop its proprietary extracellular vesicle bioproduction platform. This funding will accelerate the scale-up to achieve the first clinical grade production by the end of 2022.
Towards the emergence of new therapeutics in regenerative medicine
Despite the huge interest in EV-based therapies and their therapeutic success in preclinical studies, use of EVs in clinical setting is still in its infancy. The challenges for rendering EV-based therapies clinically feasible are a cost-effective large-scale standardized EV production complying with good manufacturing practice (GMP). Existing bottlenecks in the EV field severely hamper progress and hold back the development of new therapies:
Existing production methods have low yields, are not all scalable (production of small amounts may be quite straightforward, but manufacturing at large scale is a much more challenging problem) and are very time consuming, making these manufacturing processes not compatible with large-scale use in cost-effective conditions, and making clinical translation of EV-based therapeutics difficult.
EverZom goal is to democratize EV based therapies by bringing to the market a new EV bioproduction platform based on a disruptive manufacturing technology to accelerate the EV clinical translation and to enable new biotech stakeholders to save several years in pre-clinical and clinical development and therefore save millions of euros.
Based on a patented technology as a result of more than 10 years of academic research, EverZom innovation is a physically-triggered EV production bioinspired by a natural EV release occurring in blood vessels due to fluid shear stress. Its technology generates a turbulent flow which induces a mechanical stimulation on cells and a massive EV production. The process enables to production yields 10-fold higher and faster compared to standard production methods. In addition, the short production time enables it to work without animal proteins or human platelet lysate eliminating contamination problems encountered by traditional production methods, thus reducing the number of purification steps and processing-time.
The process preserves biophysical (structure, size, form, and purity) and biochemical (EV-specific markers indicated by the International Society of Extracellular Vesicles). The biological efficacy of EVs produced by turbulence has been confirmed by the MSC laboratory, in vitro and in three in vivo models (a heart failure regenerative model after myocardial infarction in mice; a cutaneous-digestive fistula regenerative model in rat and an esophageal stenosis regenerative model in pig).
This technology and the know-how developed around exosomes allows EVerZom to offer a scalable and reproducible exosome production process with robust quality controls. Everzom’s internal R&D is continuing its work on the link between the qualification of exosomes and their application potential. Everzom’s ambition is to become the European leader in the bioproduction of exosomes.
“We are delighted with this financing opportunity, which will enable us to industrialize our proprietary technology and meet the growing demand of the exosome market. Our ambition is to foster the emergence of new exosome therapeutic strategies and to make them accessible to the largest possible number of patients as quickly as possible” explains Jeanne Volatron, Co-founder and President of EVerZom.
Everzom business model is based on high value-added services, as well as the implementation of co-development programs of drug candidates with other pharmaceutical partners and internal proprietary programs. The company is already commercializing these biomanufacturing services to various European biotechs, in particular for the treatment of digestive fistulas by exosomes for patients that suffer from Crohn’s disease or who have undergone bariatric surgery.
Created in September 2019, EVerZom develops an industrial process for exosome bioproduction discovered by its scientific founders from the Matière et Systèmes Complexes Laboratory (MSC) of the University of Paris-CNRS. It has so far benefited from the support of the Paris Biotech Santé incubator, the Wilco healthcare accelerator, the Great Innovation Prize from the city of Paris and has been financially supported as a winner of the i-Lab competition that annually distinguishes the most disruptive French start-ups.